ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 088,24
0,89%
Dow Jones
38 239,66
0,40%
DAX
18 161,01
1,32%
Brent Oil
88,165
0,00%
Bitcoin
62 851,43
-1,39%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Ascendis Pharma AS (ASND)

  7. Ascendis Pharma AS (ASND) Actualités

ASND Ascendis Pharma AS

135,90
-1,03 (-0,75%)
27 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Ascendis Pharma AS ASND NASDAQ Certificat de dépôt
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-1,03 -0,75% 135,90 00:00:04
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
137,00 133,39 139,805 135,90 136,93
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
25/4/202422:46GLOBEAscendis Pharma to Report First Quarter 2024 Financial..
24/4/202414:30GLOBEUnited Kingdom’s MHRA Approves YORVIPATH®..
07/3/202417:31EDGAR2Form 144 - Report of proposed sale of securities
06/3/202403:39EDGAR2Form 144 - Report of proposed sale of securities
05/3/202414:14EDGAR2Form 144 - Report of proposed sale of securities
05/3/202414:04EDGAR2Form 144 - Report of proposed sale of securities
05/3/202413:37EDGAR2Form 144 - Report of proposed sale of securities
04/3/202421:17EDGAR2Form 144 - Report of proposed sale of securities
04/3/202421:07EDGAR2Form 144 - Report of proposed sale of securities
04/3/202420:54EDGAR2Form 144 - Report of proposed sale of securities
04/3/202420:36EDGAR2Form 144 - Report of proposed sale of securities
04/3/202414:30GLOBEAscendis Pharma to Participate in the Leerink Partners..
01/3/202417:00EDGAR2Form 144 - Report of proposed sale of securities
29/2/202423:13EDGAR2Form 144 - Report of proposed sale of securities
28/2/202422:49EDGAR2Form 144 - Report of proposed sale of securities
27/2/202423:45EDGAR2Form 144 - Report of proposed sale of securities
21/2/202421:17EDGAR2Form 144 - Report of proposed sale of securities
16/2/202423:16EDGAR2Form 144 - Report of proposed sale of securities
16/2/202423:15EDGAR2Form 144 - Report of proposed sale of securities
16/2/202423:14EDGAR2Form 144 - Report of proposed sale of securities
14/2/202422:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/2/202417:40EDGAR2Form 144 - Report of proposed sale of securities
14/2/202415:17EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202422:15EDGAR2Form 20-F - Annual and transition report of foreign private..
07/2/202422:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/2/202422:01GLOBEAscendis Pharma Reports Fourth Quarter and Full Year 2023..
07/2/202414:30GLOBEAscendis Pharma to Participate in the Oppenheimer 34th..
31/1/202422:15GLOBEAscendis Pharma to Report Full Year 2023 Financial Results..
31/1/202422:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/1/202422:01GLOBEAscendis Pharma Launches 2nd TransCon™ Product: YORVIPATH®..
29/1/202414:36EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/1/202414:30GLOBENew Company Eyconis Formed to Develop Ascendis Pharma..
10/1/202422:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202414:20GLOBEVector Pharma FZCO Announce Exclusive Distribution Agreement..
08/1/202412:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202412:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/1/202423:45GLOBEAscendis Pharma Introduces Vision 2030
07/1/202420:00PRNUSSpecialised Therapeutics signs exclusive agreement with..
02/1/202412:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/12/202322:15GLOBEAscendis Pharma to Participate in the 42nd Annual J.P...
20/12/202314:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202314:30GLOBESignificant Health and Quality of Life Improvements Achieved..
19/12/202322:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/12/202314:30GLOBETransCon™ hGH (lonapegsomatropin) Achieved Statistically..
13/12/202322:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/12/202314:32EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/12/202314:30GLOBEFDA Accepts for Review Resubmitted NDA for TransCon PTH..
07/12/202320:53EDGAR2Form 144 - Report of proposed sale of securities
05/12/202322:20EDGAR2Form 144 - Report of proposed sale of securities
30/11/202321:44EDGAR2Form 144 - Report of proposed sale of securities

Dernières Valeurs Consultées

NASDAQ
ASND
Ascendis Pharma AS
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés